about
Hepatitis C in haemophilia: time for treatment for all.SIPPET trial: the answers.First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.von Willebrand disease and extra-intestinal angiodysplasia.The coagulation laboratory monitoring of Afstyla single-chain FVIII concentrate.Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.Hemophilia A treatment: disruptive technology ahead.Haemophilia of the third age.Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive CommitteePrehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?Hemophilia gene therapy is effective and safeA golden age for Haemophilia treatment?Twitter and HaemophiliaHow to discuss gene therapy for haemophilia? A patient and physician perspectiveEmicizumab and thrombosis: The story so farPublishing in HaemophiliaReal-life experience in switching to new extended half-life products at European haemophilia centresManagement of comorbidities in haemophiliaThe World Federation of Hemophilia Annual Global Survey 1999-2018
P50
Q45865711-2E8E3B3F-6067-43EF-9970-085F2E17D106Q45867850-1DB7E9E7-D00B-418A-A619-3B1880D26EE3Q45868443-A16344BA-16C2-442C-8817-62B11F3DDAD7Q45868451-6E952C7D-5B37-404D-A219-136B165985B0Q45869316-F3A42A8B-1377-4596-A25B-82F6202605EAQ45871093-CD114D75-09E2-4C29-B497-10A5A14EE49DQ45884574-E8902A60-CD16-4305-BCA9-FBBD4BFEF01FQ48228134-CF134D0C-AD1C-44D1-B081-6B56C7DA899FQ60696830-875C19BA-A00C-4882-843B-A6860F3A5648Q60959329-32B8D206-B742-4401-94CA-C4195A69EFFAQ87928837-60D8F3A8-849C-4EA3-B24A-0A379FFE7045Q88226267-F50F48E8-F72A-4B34-BB53-1751C84777CEQ90511762-D191FB2A-2B0C-477A-8FBA-C15E22BE947EQ92204445-909ACFEA-C2EC-4249-BC83-1281FEC465EEQ92330948-474F0236-2140-426E-A342-ABB528CA0F48Q92552320-1EEF364A-A075-4B9F-AD3D-CF6F4BF36C01Q92659264-2E782BBA-3F25-429F-86E4-E806FEA7BEBCQ96020145-6C646695-F6AC-4EB1-87FB-22B2931EF713Q96123267-BFA9B732-5276-41A3-8A17-0FBAB406D8BD
P50
description
researcher
@en
wetenschapper
@nl
name
Michael Makris
@en
Michael Makris
@nl
type
label
Michael Makris
@en
Michael Makris
@nl
prefLabel
Michael Makris
@en
Michael Makris
@nl
P31
P496
0000-0001-7622-7939